{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:03:54Z","timestamp":1792361034145,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijrobp.2024.12.020","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T04:20:04Z","timestamp":1736050804000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Proton Beam Therapy for Pancreatic Tumors: A Consensus Statement from the Particle Therapy Cooperative Group Gastrointestinal Subcommittee"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-0914","authenticated-orcid":false,"given":"Arpit M.","family":"Chhabra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Perles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Giap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Hallemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedediah E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Diffenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Koay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Vitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith Jim","family":"Apisarnthanarax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Molitoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Romaine C.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.12.020_bib0001","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.adro.2018.04.003","article-title":"Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes","volume":"3","author":"Jethwa","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0003","first-page":"108","article-title":"Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848","volume":"6","author":"Ling","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0004","doi-asserted-by":"crossref","DOI":"10.1118\/1.4887797","article-title":"A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas","volume":"41","author":"Thompson","year":"2014","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2009.04.015","article-title":"Dose escalation with proton or photon radiation treatment for pancreatic cancer","volume":"92","author":"Bouchard","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0958-3947(01)00072-3","article-title":"Comparative treatment planning between proton and X-ray therapy in pancreatic cancer","volume":"26","author":"Hsiung-Stripp","year":"2001","journal-title":"Med Dosim"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0007","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0008","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0009","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(01)06666-1","article-title":"Continuing controversy over adjuvant therapy of pancreatic cancer","volume":"358","author":"Abrams","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijrobp.2011.05.045","article-title":"Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer","volume":"83","author":"Nichols","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.meddos.2013.11.005","volume":"39","author":"Ding","year":"2014","journal-title":"Med Dosim"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.513","article-title":"Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry","volume":"36","author":"Nichols","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0013","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1016\/j.ijrobp.2016.06.1114","article-title":"Acute toxicity of proton versus photon adjuvant chemoradiation in the treatment of pancreatic cancer: A cohort study","volume":"96","author":"Woodhouse","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0014","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ijrobp.2007.02.056","article-title":"Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment","volume":"68","author":"Kozak","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijrobp.2009.10.061","article-title":"Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head","volume":"79","author":"Hong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ijrobp.2014.03.034","article-title":"A phase 1\/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma","volume":"89","author":"Hong","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/COC.0b013e318168f6c4","article-title":"The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer","volume":"31","author":"Kinsella","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0018","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/0284186X.2012.762997","article-title":"Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity","volume":"52","author":"Nichols","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0019","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0021","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00535-013-0857-3","article-title":"Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer","volume":"49","author":"Takatori","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-022-02001-w","article-title":"Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study","volume":"17","author":"Ogura","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0023","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14338\/IJPT.14-00006.1","article-title":"Proton therapy and concomitant capecitabine for non-metastatic unresectable pancreatic adenocarcinoma","volume":"1","author":"Sachsman","year":"2014","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radio Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0025","doi-asserted-by":"crossref","first-page":"21712","DOI":"10.1038\/s41598-020-78875-1","article-title":"Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0027","doi-asserted-by":"crossref","first-page":"101250","DOI":"10.1016\/j.adro.2023.101250","article-title":"Proton therapy for unresectable and medically inoperable locally advanced pancreatic cancer: Results from a multi-institutional prospective registry","volume":"8","author":"Eckstein","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0028","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0029","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semradonc.2020.02.007","article-title":"Proton reirradiation: Expert recommendations for reducing toxicities and offering new chances of cure in patients with challenging recurrence malignancies","volume":"30","author":"Simone","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2017.08.005","article-title":"Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation","author":"Verma","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0031","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/jgo.2017.03.04","article-title":"Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma","author":"Boimel","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.adro.2017.01.003","article-title":"Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma","volume":"2","author":"Koong","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0033","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/acm2.13429","article-title":"Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer","volume":"22","author":"Narita","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0034","series-title":"Radiation Therapy for Gastrointestinal Cancers","year":"2017"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.adro.2018.07.008","article-title":"Dose escalation for locally advanced pancreatic cancer: How high can we go?","volume":"3","author":"Colbert","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0036","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/j.prro.2020.01.012","article-title":"Dose-escalated radiation therapy for pancreatic cancer: A simultaneous integrated boost approach","volume":"10","author":"Koay","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0037","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.prro.2020.01.007","article-title":"Evaluation of the visibility and artifacts of 11 common fiducial markers for image guided stereotactic body radiation therapy in the abdomen","volume":"10","author":"Slagowski","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.830080","article-title":"Experimental comparison of fiducial markers used in proton therapy: Study of different imaging modalities and proton fluence perturbations measured with CMOS pixel sensors","volume":"12","author":"Reidel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0039","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1088\/0031-9155\/52\/11\/001","article-title":"Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate","volume":"52","author":"Newhauser","year":"2007","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0040","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1088\/0031-9155\/56\/16\/014","article-title":"Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate","volume":"56","author":"Huang","year":"2011","journal-title":"Phys Med Biol"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2024.12.020_bib0041","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1093\/jrr\/rrt071","article-title":"Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy","volume":"54","author":"Habermehl","year":"2013","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0042","doi-asserted-by":"crossref","first-page":"E766","DOI":"10.1055\/a-0588-4800","article-title":"Knowledge of endoscopic ultrasound-delivered fiducial composition and dimension necessary when planning proton beam radiotherapy","volume":"6","author":"Gleeson","year":"2018","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0043","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1120\/jacmp.v10i1.2875","article-title":"Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer","volume":"10","author":"Giebeler","year":"2009","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0044","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1088\/0031-9155\/55\/23\/S13","article-title":"Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer","volume":"55","author":"Cheung","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1533034614547447","article-title":"Qualitative evaluation of fiducial markers for radiotherapy imaging","volume":"14","author":"Chan","year":"2015","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0046","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijrobp.2016.10.022","article-title":"Clinical implementation of dual-energy CT for proton treatment planning on pseudo-monoenergetic CT scans","volume":"97","author":"Wohlfahrt","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0047","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2016.02.026","article-title":"Dual energy CT in radiotherapy: Current applications and future outlook","volume":"119","author":"van Elmpt","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0048","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200170","article-title":"Feasibility of using post-contrast dual-energy CT for pediatric radiation treatment planning and dose calculation","volume":"94","author":"Ates","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0049","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1088\/1361-6560\/aa7dc9","article-title":"Comprehensive analysis of proton range uncertainties related to stopping-power-ratio estimation using dual-energy CT imaging","volume":"62","author":"Li","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0050","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1118\/1.2349696","article-title":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","volume":"33","author":"Keall","year":"2006","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0051","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1088\/1361-6560\/aa66c5","article-title":"Surface as a motion surrogate for gated re-scanned pencil beam proton therapy","volume":"62","author":"Zhang","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0052","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phro.2021.07.006","article-title":"Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance-linac system using abdominal compression","volume":"19","author":"Tyagi","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0053","doi-asserted-by":"crossref","DOI":"10.1118\/1.4819940","article-title":"Interfraction variation in lung tumor position with abdominal compression during stereotactic body radiotherapy","volume":"40","author":"Mampuya","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0054","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejmp.2015.12.009","article-title":"Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study","volume":"32","author":"Sio","year":"2016","journal-title":"Phys Med"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1118\/1.3679340","article-title":"Robust optimization of intensity modulated proton therapy","volume":"39","author":"Liu","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0056","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2018.01.019","article-title":"A statistical comparison of motion mitigation performances and robustness of various pencil beam scanned proton systems for liver tumour treatments","volume":"128","author":"Zhang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0057","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1088\/0031-9155\/56\/20\/003","article-title":"Dosimetric consequences of tumour motion due to respiration for a scanned proton beam","volume":"56","author":"Kraus","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0058","series-title":"Target Volume Delineation and Treatment Planning for Particle Therapy: A Practical Guide","first-page":"45","article-title":"Proton treatment planning","author":"Zeng","year":"2018"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0059","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.ijrobp.2016.03.041","article-title":"Clinically applicable Monte Carlo-based biological dose optimization for the treatment of head and neck cancers with spot-scanning proton therapy","volume":"95","author":"Wan Chan Tseung","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0060","doi-asserted-by":"crossref","DOI":"10.1118\/1.4901522","article-title":"A GPU-accelerated and Monte Carlo-based intensity modulated proton therapy optimization system","volume":"41","author":"Ma","year":"2014","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0061","article-title":"Charged particle irradiation for pancreatic cancer: A systematic review of in vitro studies","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0062","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ijrobp.2024.04.003","article-title":"Reduced risk of severe radiation-induced lymphopenia in carbon ion radiation therapy for locally advanced pancreatic cancer: A comparative analysis of carbon versus photon therapy","volume":"120","author":"Yang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.12.020_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2023.101250","article-title":"Proton therapy for unresectable and medically inoperable locally advanced pancreatic cancer: Results from a multi-institutional prospective registry","author":"Eckstein","year":"2023","journal-title":"Adv Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:26:51Z","timestamp":1744619211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624037696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0360301624037696"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.020","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Beam Therapy for Pancreatic Tumors: A Consensus Statement from the Particle Therapy Cooperative Group Gastrointestinal Subcommittee","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}